Pharmacogenetic testing for warfarin dosing still awaits validation

Journal of the American College of Cardiology

Volumn 57, Issue 6, 2011, Pages 756-

  Lefevre, Frank ^a   Goodman, Steven N ^b   Piper, Margaret A ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

LETTER; PATIENT SELECTION; PHARMACOGENETICS; PRIORITY JOURNAL; STUDY DESIGN; VALIDATION PROCESS;

ANTICOAGULANTS; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; PHARMACOGENETICS; THROMBOEMBOLISM; WARFARIN;

EID: 79551568045     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.07.057     Document Type: Letter

References (4)

1. R.S. Epstein, T.P. Moyer, and R.E. Aubert Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study) J Am Coll Cardiol 2010 2804 2812
2. K.D. Lindsted, G.E. Fraser, M. Steinkohl, and W.L. Beeson Healthy volunteer effect in a cohort study: temporal resolution in the Adventist Health Study J Clin Epidemiol 49 1996 783 790
3. P. Froom, S. Melamed, E. Kristal-Boneh, J. Benbassat, and J. Ribak Healthy volunteer effect in industrial workers J Clin Epidemiol 52 1999 731 735
4. G.S. Ginsburg, and D. Voora The long and winding road to warfarin pharmacogenetic testing J Am Coll Cardiol 55 2010 2813 2815